Royalty Pharma plc is identified as one of the top 10 overlooked healthcare stocks to invest in, holding interests in 35+ commercial products like Trikafta and Tremfya. In Q2 2025, the company reported Portfolio Receipts of $727 million, a 20% YoY increase, with Royalty Receipts up 11% to $672 million. The acquisition of RP Management, LLC and deals with Revolution Medicines and Amgen further strengthened its portfolio. Looking ahead, Royalty Pharma plc anticipates 2025 Portfolio Receipts to grow by 9-12%.

Read more at Yahoo Finance: Royalty Pharma plc (RPRX) Boosts Growth with $885M Amgen Imdelltra Royalty Deal